NanoCarrier Co., Ltd.

Tokyo Stock Exchange 4571.T

NanoCarrier Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD 24.63 K

NanoCarrier Co., Ltd. Net Cash Used Provided By Financing Activities is USD 24.63 K for the year ending March 31, 2024, a -89.84% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

NanoCarrier Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD 242.36 K, a -97.43% change year over year.
NanoCarrier Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD 9.41 M, a 9,195.35% change year over year.
NanoCarrier Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD -103.49 K, a -100.51% change year over year.
NanoCarrier Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD 20.10 M, a -34.16% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Tokyo Stock Exchange: 4571.T

NanoCarrier Co., Ltd.

CEO	Dr. Shiro Akinaga Ph.D.
IPO Date	March 5, 2008
Location	Japan
Headquarters	Onoya-Kyobashi Building
Employees	18
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Clinical Trials Pharmaceuticals Vaccines

Description

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years